SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials

SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials

Acute heart failure (AHF) is a major public health concern, affecting 26 million worldwide. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of glucose-lowering drugs, comprising canagliflozin, dapagliflozin, and empagliflozin that are being explored for AHF. We aim to meta-analyze the...

Full description

Bibliographic Details
Main Authors: Noor Ul Amin, Faiza Sabir, Talal Amin, Zouina Sarfraz, Azza Sarfraz, Karla Robles-Velasco, Ivan Cherrez-Ojeda
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Healthcare
Subjects:
acute heart failure
SGLT2 inhibitors
cardioprotection
cardiovascular mortality
heart failure events
Online Access:https://www.mdpi.com/2227-9032/10/12/2356

Internet

https://www.mdpi.com/2227-9032/10/12/2356

Similar Items